Aptus Pharma Shareholders Approve Bonus Issue and Capital Increase

Aptus Pharma Ltd shareholders have unanimously approved a 3:2 bonus share issuance and a substantial increase in authorized share capital from ₹7.15 crore to ₹25 crore.

Shareholder Approval Details

Aptus Pharma Limited announced that shareholders overwhelmingly approved two key resolutions via postal ballot. Both received unanimous support, with 100% of the 5,122,000 votes cast in favor.

Shareholders approved a significant increase in the company's authorized share capital from ₹7.15 crore to ₹25 crore. This move enhances financial flexibility for future initiatives. The second approval is for a 3:2 bonus share issuance, meaning shareholders will receive three new shares for every two held.

The postal ballot concluded on April 25, 2026, with the scrutinizer's report confirming the unanimous decision and indicating strong shareholder confidence.

Investor and Company Benefits

Bonus shares directly reward existing shareholders by increasing their share count without requiring new investment. This can potentially boost share liquidity and stock appeal.

The increased authorized share capital gives Aptus Pharma greater financial flexibility to pursue expansion projects, acquisitions, or other corporate actions.

Company Background and Performance

Aptus Pharma operates an asset-light model focused on marketing and distributing pharmaceutical formulations via contract manufacturing. The company recently concluded its Initial Public Offering (IPO) in September 2025.

The company's board had approved these proposals on March 24, 2026. Aptus Pharma had not issued major bonus shares or substantially increased its authorized share capital in the prior 24 months.

The company has seen significant stock appreciation, with its share price surging approximately 219.0% in the last six months. Recent financial results show strong growth: revenue increased 47% and net profit rose 34% in the latest reported period.

Key Implications

Shareholders will receive additional shares through the 3:2 bonus issue, increasing their total holdings.

The company gains enhanced financial flexibility, positioning it better for strategic growth opportunities and future capital needs.

Earnings Per Share (EPS) will be adjusted due to the higher number of outstanding shares, though total shareholder equity value is expected to remain unchanged initially.

Industry Comparison

In contrast to Aptus Pharma's bonus share issuance, many larger Indian pharmaceutical peers like Divi's Laboratories, Lupin, Aurobindo Pharma, and Sun Pharmaceutical typically prioritize organic growth and are more selective with bonus shares.

What to Watch Next

Monitor Aptus Pharma's announcements for the official timeline for the authorized share capital increase.

Track the record date and credit date for the 3:2 bonus share distribution.

Observe how the company uses its enhanced capital flexibility for future growth initiatives or acquisitions.

Monitor the company's financial performance post-bonus issue, particularly how EPS metrics evolve.

Assess the market's reaction to the increased share count and its potential impact on stock liquidity.